300832.SZ
BuyFallen FavouriteAI neutralShenzhen New Industries Biomedical Engineering Co., Ltd. · Healthcare · China · $6.7B cap · $44.8M/day traded
CNY 56.66 +5.7% · close 23 Oct · scored 24 Oct
StockRank up 1.6 since 23 Oct.
Fallen Favourite: A good business, still expensive, and the price is falling.
As of 24 Oct 2026, MoatMap's StockRank for Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) is 76/100, ranked against 24,000+ stocks in 35 markets (Quality 83, Value 41, Momentum 47, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Shenzhen New Industries Biomedical (Snibe) is one of China's leading makers of chemiluminescence immunoassay analysers and reagents, a razor-and-blade model with high margins and strong returns on capital. It is gaining share from foreign brands and growing overseas, management is buying back stock, and insiders have made small purchases. However, forward earnings estimates were cut about 4% over the past month as volume-based procurement and hospital anti-corruption measures weigh on domestic pricing and test volumes.
ABOUT SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
Read
Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) is a leading global manufacturer of in vitro diagnostic (IVD) instruments and reagents, specializing in chemiluminescence immunoassay (CLIA) technology. The company's competitive moat is anchored by its massive installed base of diagnostic analyzers, which generates highly recurring, high-margin reagent sales. As a pioneer in domestic CLIA technology, Snibe is a major player in both the Chinese healthcare system and expanding international markets.
FINANCIAL SUMMARY (CNY)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.0B | 3.9B | 4.5B | 4.6B | 14.5% | 4.8B | 5.2B | 5.9B | 13.3% |
| EPS (CNY) | 1.69 | 2.11 | 2.33 | 2.06 | 6.8% | 2.19 | 2.53 | 2.94 | 19.3% |
| Shares | 786.1M | 785.7M | 785.7M | 785.7M | -0.1% | 785.7M | — | — | — |
| Debt | 2.2M | 5.2M | 4.1M | 3.7M | 18.4% | 3.3M | — | — | — |
| Equity | 6.4B | 7.5B | 8.6B | 9.1B | 12.6% | — | — | — | — |
| Op CF | 962.4M | 1.4B | 1.4B | 1.5B | 16.5% | 2.0B | — | — | — |
| Inv CF | -593.7M | -290.7M | -705.2M | -413.4M | — | — | — | — | — |
| Fin CF | -497.4M | -568.6M | -790.2M | -1.0B | — | — | — | — | — |
51% above its 52-week low and back above a rising 50-day average.
The Momentum score still reads 47: it weighs six months of price and earnings revisions, so it trails a turn like this.
Calmer than 66% of stocks we rank over the past year (33% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300832.SZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 300832.SZ | Shenzhen New Industries Biomedical Engineering Co., Ltd.(you) | $6.7B | 76 | Buy |
| 688617.SS | APT Medical Inc. | $5.7B | 65 | Buy |
| 603658.SS | Autobio Diagnostics Co., Ltd. | $3.0B | 84 | Strong Buy |
| 002901.SZ | Double Medical Technology Inc. | $2.4B | 69 | Buy |
| 002223.SZ | Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. | $4.1B | 59 | Hold |
| 301087.SZ | Cofoe Medical Technology Co.,Ltd. | $1.9B | 74 | Buy |
| 688016.SS | Shanghai MicroPort Endovascular MedTech Co., Ltd. | $1.6B | 72 | Buy |
| 600587.SS | Shinva Medical Instrument Co.,Ltd. | $1.2B | 76 | Buy |
| 603014.SS | Shandong Weigao Blood Purification Products Co., Ltd. | $3.1B | 56 | Hold |
| 300206.SZ | Edan Instruments, Inc. | $965M | 78 | Buy |
Peer medians: ROE 4.3% · P/E 27.2x · Gross margin 53.1%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.